BioXcel Therapeutics (BTAI) Interest Coverage Ratio (2017 - 2026)
BioXcel Therapeutics' (BTAI) quarterly Interest Coverage Ratio came in at 2.44 in Q1 2026, up 3.72% year-on-year from 2.35 in Q1 2025, and down 4.12% quarter-over-quarter from 2.34 in Q4 2025.
BioXcel Therapeutics (BTAI) Interest Coverage Ratio (2017 - 2026) Analysis & Trends
BioXcel Therapeutics' Interest Coverage Ratio history runs 10 years deep, the most recent figure standing at 2.44 for Q1 2026.
- On a quarterly basis, Interest Coverage Ratio rose 3.72% year-over-year to 2.44 in Q1 2026; TTM through Mar 2026 was 3.02, a 51.16% increase from a year earlier, with the FY2025 full-year figure at 2.97, down 748.97% from the prior year.
- Interest Coverage Ratio retreated to 2.44 in Q1 2026 per BTAI's latest filing, from 2.34 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 3.64 in Q4 2024 and bottomed at 6.7 in Q1 2024.
- The 5-year median for Interest Coverage Ratio is 2.53 (2025), against an average of 3.0.
- Across the five-year window, Interest Coverage Ratio sank 1321.96% in 2023 and surged 157.26% in 2024, its largest moves.
- Year by year, Interest Coverage Ratio stood at 0.45 in 2022, then sank by 1321.96% to 6.35 in 2023, then surged by 157.26% to 3.64 in 2024, then slumped by 164.29% to 2.34 in 2025, then dropped by 4.12% to 2.44 in 2026.
- Per Business Quant, the three latest BTAI Interest Coverage Ratio figures stand at 2.44 (Q1 2026), 2.34 (Q4 2025), and 3.62 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 13.44 |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -2.81 |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 0.18 |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -0.07 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 0.33 |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 5.11 |
| 10 | BioXcel Therapeutics | 10.62 Mn | 10.62 Mn | -77,000.00 | -2.44 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.44 |
| Dec 31, 2025 | -2.34 |
| Sep 30, 2025 | -3.62 |
| Jun 30, 2025 | -3.75 |
| Mar 31, 2025 | -2.53 |
| Dec 31, 2024 | 3.64 |
| Sep 30, 2024 | -4.04 |
| Jun 30, 2024 | -4.67 |
| Mar 31, 2024 | -6.70 |
| Dec 31, 2023 | -6.35 |
| Sep 30, 2023 | -6.60 |
| Jun 30, 2023 | -5.69 |
| Mar 31, 2023 | -1.42 |
| Dec 31, 2022 | -0.45 |
| Sep 30, 2022 | -1.91 |
| Jun 30, 2022 | -1.53 |
| Mar 31, 2022 | -0.67 |
| Dec 31, 2021 | -4,355.17 |
| Sep 30, 2021 | -0.40 |
| Jun 30, 2021 | -1,725.81 |